XML 19 R9.htm IDEA: XBRL DOCUMENT
v3.25.3

NET SALES | 9 Months Ended
--- | ---
Sep. 30, 2025
Revenue from Contract with Customer [Abstract] |
NET SALES | NOTE 3. NET SALES Revenue Recognition Revenue under contract manufacturing agreements that was recognized over time, excluding noncash consideration, accounted for 75% of net sales for both the three and nine months ended September 30, 2025 and 72% and 73% of net sales for the three and nine months ended September 30, 2024, respectively. The following tables summarize our net sales by market for the three and nine months ended September 30, 2025 and 2024, respectively: SCHEDULE OF NET SALES BY MARKET
|  | Product/ Service Transferred Over Time |  |  | Product Transferred at Point in Time |  |  | Noncash Consideration1 |  |  | Total Net Sales by Market |
|  | Three Months Ended September 30, 2025 |
|  | Product/ Service Transferred Over Time |  |  | Product Transferred at Point in Time |  |  | Noncash Consideration1 |  |  | Total Net Sales by Market |
Medical Device |  | $ | 5,758 |  |  | $ | 2,004 |  |  | $ | 589 |  |  | $ | 8,351 |
Medical Imaging |  |  | 8,215 |  |  |  | 2,169 |  |  |  | 5 |  |  |  | 10,389 |
Industrial |  |  | 6,163 |  |  |  | 1,798 |  |  |  | 251 |  |  |  | 8,212 |
Aerospace and Defense |  |  | 2,576 |  |  |  | 886 |  |  |  | 68 |  |  |  | 3,530 |
Total net sales |  | $ | 22,712 |  |  | $ | 6,857 |  |  | $ | 913 |  |  | $ | 30,482 |
|  | Product/ Service Transferred Over Time |  |  | Product Transferred at Point in Time |  |  | Noncash Consideration1 |  |  | Total Net Sales by Market |
|  | Three Months Ended September 30, 2024 |
|  | Product/ Service Transferred Over Time |  |  | Product Transferred at Point in Time |  |  | Noncash Consideration1 |  |  | Total Net Sales by Market |
Medical Device(2) |  | $ | 5,505 |  |  | $ | 2,087 |  |  | $ | 898 |  |  | $ | 8,490 |
Medical Imaging(2) |  |  | 7,206 |  |  |  | 2,348 |  |  |  | 3 |  |  |  | 9,557 |
Industrial |  |  | 5,505 |  |  |  | 2,667 |  |  |  | 262 |  |  |  | 8,434 |
Aerospace and Defense |  |  | 4,394 |  |  |  | 494 |  |  |  | 38 |  |  |  | 4,926 |
Total net sales |  | $ | 22,610 |  |  | $ | 7,596 |  |  | $ | 1,201 |  |  | $ | 31,407 |
|  | Product/ Service Transferred Over Time |  |  | Product Transferred at Point in Time |  |  | Noncash Consideration1 |  |  | Total Net Sales by Market |
|  | Nine Months Ended September 30, 2025 |
|  | Product/ Service Transferred Over Time |  |  | Product Transferred at Point in Time |  |  | Noncash Consideration1 |  |  | Total Net Sales by Market |
Medical Device |  | $ | 16,579 |  |  | $ | 5,738 |  |  | $ | 1,654 |  |  | $ | 23,971 |
Medical Imaging |  |  | 22,413 |  |  |  | 6,211 |  |  |  | 17 |  |  |  | 28,641 |
Industrial |  |  | 17,459 |  |  |  | 5,729 |  |  |  | 485 |  |  |  | 23,673 |
Aerospace and Defense |  |  | 9,333 |  |  |  | 2,250 |  |  |  | 184 |  |  |  | 11,767 |
Total net sales |  | $ | 65,784 |  |  | $ | 19,928 |  |  | $ | 2,340 |  |  | $ | 88,052 |
|  | Product/ Service Transferred Over Time |  |  | Product Transferred at Point in Time |  |  | Noncash Consideration1 |  |  | Total Net Sales by Market |
|  | Nine Months Ended September 30, 2024 |
|  | Product/ Service Transferred Over Time |  |  | Product Transferred at Point in Time |  |  | Noncash Consideration1 |  |  | Total Net Sales by Market |
Medical Device(2) |  | $ | 17,178 |  |  | $ | 6,919 |  |  | $ | 2,396 |  |  | $ | 26,493 |
Medical Imaging(2) |  |  | 20,291 |  |  |  | 7,193 |  |  |  | 14 |  |  |  | 27,498 |
Industrial |  |  | 18,847 |  |  |  | 7,682 |  |  |  | 1,114 |  |  |  | 27,643 |
Aerospace and Defense |  |  | 16,494 |  |  |  | 1,231 |  |  |  | 154 |  |  |  | 17,879 |
Total net sales |  | $ | 72,810 |  |  | $ | 23,025 |  |  | $ | 3,678 |  |  | $ | 99,513 |
1 | Noncash consideration represents material provided by the customer used in the manufacturing of the product.
2 | Medical, as reported in the prior-year period filing, has been split between Medical Device and Medical Imaging to conform with the current-year presentation.
Contract Assets Contract assets, recorded in the condensed consolidated balance sheets, consist of unbilled amounts related to revenue recognized over time. Significant changes in the contract assets balance during the nine months ended September 30, 2025 were as follows: SCHEDULE OF CONTRACT ASSETS
Balance as of December 31, 2024 |  | $ | 13,792 |
Increase (decrease) attributed to: |  |  |  |
Amounts transferred over time to contract assets |  |  | 65,784 |
Allowance for current expected credit losses |  |  | (1 | )
Amounts invoiced during the period |  |  | (64,247 | )
Balance outstanding as of September 30, 2025 |  | $ | 15,328 |
We expect substantially all the remaining performance obligations for the contract assets recorded as of September 30, 2025 to be transferred to receivables within 90 days, with any remaining amounts to be transferred within 180 days. We bill our customers upon shipment with payment terms of up to 120 days.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration